Patents by Inventor Yuelei SHEN

Yuelei SHEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-PD-L1 ANTIBODY AND USE THEREOF
    Publication number: 20220073621
    Abstract: The present application provides an anti-PD-L1 antibody, an antigen-binding fragment thereof, and use thereof. The present application also provides a multispecific antibody such as a bispecific antibody, a conjugate, and a composition comprising the anti-PD-L1 antibody or the antigen-binding fragment thereof, and use thereof in treatment of diseases such as cancer.
    Type: Application
    Filed: August 20, 2020
    Publication date: March 10, 2022
    Inventors: Yi Yang, Jingshu Xie, Chunyan Dong, Fang Yang, Chengyuan Lu, Yuelei Shen, Jian Ni, Ya'nan Guo, Yunyun Chen
  • Genetically modified non-human animal with human or chimeric TIM-3
    Patent number: 11240995
    Abstract: The present disclosure relates to the genetically modified non-human animals that express a human or chimeric (e.g., humanized) T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), and methods of use thereof.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: February 8, 2022
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Jian Ni, Yanan Guo, Rui Huang, Meiling Zhang, Lei Zhao, Yang Bai
  • Method for constructing PD-1 gene modified humanized animal model and use thereof
    Patent number: 11234420
    Abstract: Provided is a method for preparing a PD-1 gene-modified humanized animal model. The method utilizes the CRIPSR/Cas9 technique to replace partial fragments of a mouse PD-1 gene with fragments of a human PD-1 gene using homologous recombination by constructing a targeting vector, thereby preparing a gene-modified humanized mouse. This mouse can normally express a PD-1 protein containing the functional domain of the human PD-1 protein, and can be used as an animal model for mechanism research regarding PD-1, PD-L1 and other signals, for screening regulators, and for toxicological research. The method has an important and high application value in studies on functions of the PD-1 gene and in the development of new drugs.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: February 1, 2022
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Yang Bai, Rui Huang, Xiaofei Zhou, Yuting Hu, Yanan Guo, Jichao Du
  • Genetically modified non-human animal with human or chimeric IL15
    Patent number: 11234421
    Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) IL15, and methods of use thereof.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: February 1, 2022
    Assignees: Biocytogen JiangSu Co., Ltd., Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Meiling Zhang, Jiawei Yao, Chaoshe Guo, Yanan Guo, Yang Bai, Rui Huang, Lei Zhao
  • GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GENES
    Publication number: 20220015343
    Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) IL6R and/or IL6, and methods of use thereof.
    Type: Application
    Filed: December 17, 2019
    Publication date: January 20, 2022
    Inventors: Yuelei Shen, Meiling Zhang, Jiawei Yao, Chaoshe Guo, Yanan Guo, Yang Bai, Rui Huang, Lei Zhao, Chengzhang Shang
  • GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GENES
    Publication number: 20220000086
    Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) IL4R and/or IL4, and methods of use thereof.
    Type: Application
    Filed: September 23, 2021
    Publication date: January 6, 2022
    Inventors: Yuelei Shen, Yanan Guo, Yang Bai, Rui Huang, Xiaofei Zhou, Chengzhang Shang, Meiling Zhang, Jiawei Yao, Chaoshe Guo
  • ANTI-CD40 ANTIBODIES AND USES THEREOF
    Publication number: 20210403588
    Abstract: This disclosure relates to anti-CD40 (TNF Receptor Superfamily Member 5) antibodies, antigen-binding fragments, and the uses thereof.
    Type: Application
    Filed: September 8, 2021
    Publication date: December 30, 2021
    Inventors: Yi Yang, Chunyan Dong, Fang Yang, Chengyuan Lu, Yuelei Shen, Jian Ni, Yanan Guo, Yunyun Chen, Jingshu Xie
  • GENETICALLY MODIFIED ANIMAL WITH CANINE OR CHIMERIC PD-1
    Publication number: 20210400933
    Abstract: The present disclosure relates to genetically modified animals that express a canine or chimeric (e.g., caninized) programmed cell death protein 1 (PD-1), and methods of use thereof.
    Type: Application
    Filed: November 19, 2019
    Publication date: December 30, 2021
    Inventors: Yuelei Shen, Yang Bai, Rui Huang, Xiaofei Zhou, Chengzhang Shang, Meiling Zhang, Jiawei Yao, Chaoshe Guo, Yanan Guo
  • ANTI-PD-1 ANTIBODIES AND USES THEREOF
    Publication number: 20210403570
    Abstract: This disclosure relates to anti-PD-1 (Programmed Cell Death Protein 1) antibodies, antigen-binding fragments, and the uses thereof.
    Type: Application
    Filed: September 17, 2021
    Publication date: December 30, 2021
    Inventors: Yi Yang, Jingshu Xie, Chunyan Dong, Fang Yang, Chengyuan Lu, Xiaodong Cheng, Yuelei Shen, Jian Ni, Yanan Guo, Yunyun Chen
  • Genetically modified non-human animal with human or chimeric genes
    Patent number: 11154041
    Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) IL4R and/or IL4, and methods of use thereof.
    Type: Grant
    Filed: September 2, 2020
    Date of Patent: October 26, 2021
    Assignees: Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Biocytogen JiangSu Co., Ltd.
    Inventors: Yuelei Shen, Yanan Guo, Yang Bai, Rui Huang, Xiaofei Zhou, Chengzhang Shang, Meiling Zhang, Jiawei Yao, Chaoshe Guo
  • Genetically modified non-human animal with human or chimeric CD137
    Patent number: 11154040
    Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD137, and methods of use thereof.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: October 26, 2021
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Yanan Guo, Yang Bai, Lei Zhao, Rui Huang, Jiawei Yao, Meiling Zhang
  • Anti-PD-1 antibodies and uses thereof
    Patent number: 11155625
    Abstract: This disclosure relates to anti-PD-1 (Programmed Cell Death Protein 1) antibodies, antigen-binding fragments, and the uses thereof.
    Type: Grant
    Filed: July 2, 2020
    Date of Patent: October 26, 2021
    Assignee: Eucure (Beijing) Biopharma Co., Ltd
    Inventors: Yi Yang, Jingshu Xie, Chunyan Dong, Fang Yang, Chengyuan Lu, Xiaodong Cheng, Yuelei Shen, Jian Ni, Yanan Guo, Yunyun Chen
  • Anti-CD40 antibodies and uses thereof
    Patent number: 11142582
    Abstract: This disclosure relates to anti-CD40 (TNF Receptor Superfamily Member 5) antibodies, antigen-binding fragments, and the uses thereof.
    Type: Grant
    Filed: January 14, 2021
    Date of Patent: October 12, 2021
    Assignee: Eucure (Beijing) Biopharma Co., Ltd
    Inventors: Yi Yang, Chunyan Dong, Fang Yang, Chengyuan Lu, Yuelei Shen, Jian Ni, Yanan Guo, Yunyun Chen, Jingshu Xie
  • ANTI-PD-1 ANTIBODIES AND USES THEREOF
    Publication number: 20210284735
    Abstract: This disclosure relates to anti-PD-1 (Programmed Cell Death Protein 1) antibodies, antigen-binding fragments, and the uses thereof.
    Type: Application
    Filed: May 19, 2021
    Publication date: September 16, 2021
    Inventors: Yi Yang, Chunyan Dong, Fang Yang, Chengyuan Lu, Yuelei Shen, Jian Ni, Yanan Guo, Yunyun Chen, Jingshu Xie
  • ANTI-CD3e ANTIBODIES AND USES THEREOF
    Publication number: 20210269525
    Abstract: This disclosure relates to anti-CD3e (T-cell surface glycoprotein CD3 epsilon chain) antibodies, antigen-binding fragments, and the uses thereof.
    Type: Application
    Filed: June 19, 2019
    Publication date: September 2, 2021
    Inventors: Yi Yang, Yunyun Chen, Jingshu Xie, Chunyan Dong, Fang Yang, Chengyuan Lu, Xiaodong Cheng, Yuelei Shen, Jian Ni, Yanan Guo
  • GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD3e
    Publication number: 20210259220
    Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD3e (T-cell surface glycoprotein CD3 epsilon chain), and methods of use thereof.
    Type: Application
    Filed: February 5, 2021
    Publication date: August 26, 2021
    Inventors: Yuelei Shen, Yanan Guo, Rui Huang, Xiaofei Zhou, Yang Bai, Jiawei Yao, Chaoshe Guo
  • Method of using a genetically modified mouse that expresses a humanized CTLA-4 gene
    Patent number: 11096383
    Abstract: The present disclosure relates to the genetically modified non-human animals that express a human or chimeric CTLA-4, and methods of use thereof.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: August 24, 2021
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Yanan Guo, Yang Bai, Jiawei Yao, Chengzhang Shang, Rui Huang
  • DNA knock-in system
    Patent number: 11071289
    Abstract: The present disclosure relates to an efficient genome editing technique. In one aspect, the technique can greatly improve the efficiency of homologous recombination during intracellular targeting, including gene targeting. Using this technique, genetically modified cell lines, rat, mouse, zebrafish, and fertilized eggs of other species can be quickly and efficiently generated.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: July 27, 2021
    Assignee: Biocytogen Boston Corp
    Inventor: Yuelei Shen
  • Genetically modified non-human animal with human or chimeric CTLA-4
    Patent number: 11071290
    Abstract: The present disclosure relates to the genetically modified non-human animals that express a human or chimeric CTLA-4, and methods of use thereof.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: July 27, 2021
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Yanan Guo, Yang Bai, Jiawei Yao, Chengzhang Shang, Rui Huang
  • ANTI-TNFRSF9 ANTIBODIES AND USES THEREOF
    Publication number: 20210206867
    Abstract: This disclosure relates to anti-TNFRSF9 (tumor necrosis factor receptor superfamily member 9) antibodies, antigen-binding fragments, and the uses thereof.
    Type: Application
    Filed: March 12, 2021
    Publication date: July 8, 2021
    Inventors: Yi Yang, Jingshu Xie, Chunyan Dong, Fang Yang, Chengyuan Lu, Yuelei Shen, Jian Ni, Yanan Guo, Yunyun Chen